Ecnoglutide yields superior, sustained reduction in body weight: Study

For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon-like peptide 1 receptor agonist known as ecnoglutide yields a superior and sustained reduction in body weight versus placebo, according to a study published online June 21 in The Lancet Diabetes & Endocrinology to coincide with the annual meeting of the American Diabetes Association, held from June 20 to 23 in Chicago.
Read More

Novel therapy saves patient with severe heart inflammation

Acute myocarditis—sudden inflammation of the heart—causes mild symptoms in most cases, but about 10% of acute myocarditis cases can be sudden and severe, leading to cardiac arrhythmias, heart pump failure, or even death. Current therapies for the condition are built on limited data and may not effectively target the underlying disease mechanisms. Patients may even require mechanical circulatory support for life support when the heart is failing.
Read More
Top